From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic Therapeutics.

Abstract

Two recent patent applications illustrate how psychedelic drug development is expanding beyond molecules and experiences toward deployable therapeutic systems. One focuses on solid-state optimization of a lysergamide analogue to ensure manufacturability and stability, while the other applies machine-learning-driven neurophysiological biomarkers to predict patient response. Together, they address complementary translational bottlenecks in psychedelic medicine.